The study of SB5 vs. Humira in subjects with moderate to severe chronic plaque psoriasis

illustrative image

The company Samsung Bioepis Co., Ltd is commencing recruitment for the clinical trial of the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis.

The trial officially began on the August 4, 2022 and is planned to complete on September 2023.

This is a Phase IV, randomized, double-blind, parallel-group, multiple-dose, active comparator, multicenter clinical study to evaluate the pharmacokinetic, efficacy, safety, and immunogenicity of SB5 versus Humira in subjects with moderate to severe chronic plaque psoriasis.

The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT05510063.

Clinical Research News

Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products
Submission of comments on ICH E6 (R3) Guideline for Good Clinical Practice(GCP) - Step 2b 
ICH E6(R3) Good Clinical Practice guidance - Step 2 Public Consultation
The study of the new investigational drug for acute myeloid leukemia and myelodysplastic syndrome
Open Label study of entrectinib in ROS1 gene fusion-positive rare adult, paediatric and teenage/young adult cancers
Gasherbrum Bio, Inc is starting the study of GSBR-1290 drug in overweight or obese healthy adults
A new study of Dexpramipexole in adolescents and adults with severe Eosinophilic Asthma

Upcoming Clinical Trials

The study of SB5 vs. Humira in subjects with moderate to severe chronic plaque psoriasis

All jobs

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe